SCHEMBL1121841

SCHEMBL1121841

O=C(O)N1CC(CS(=O)(=O)c2ccc(F)cc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP14 P50281 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CRBN Q96SW2 1/20 0.43
HSD11B1 P28845 2/20 0.42
CYP2C19 P33261 2/20 0.42
MAPT P10636 1/20 0.42
CYP3A4 P08684 1/20 0.42
AOC2 O75106 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
EIF4H Q15056 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3040016 0.85 L3MBTL1 (0.46) NPC1RAB9ACRBNCYP2C19MAPT
Hydrochloric Acid SCHEMBL3043138 0.84 L3MBTL1 (0.45) NPC1RAB9ACRBNCYP2C19MAPT
SCHEMBL5827056 0.81 AGTR2 (0.38) MMP2NPC1AOC2POLBKMT2A
SCHEMBL1121623 0.81 MAPT (0.43) MAPTAOC2
SCHEMBL1121933 0.79 MMP13 (0.47) KMT2A
SCHEMBL23245900 0.77 CA1 (0.47) NPC1RAB9AMAPTCA12CA1
SCHEMBL21412332 0.77 CA1 (0.47) NPC1RAB9AMAPTCA12CA1
SCHEMBL1121996 0.77 HTR2A (0.52) HSD11B1CYP2C19MAPTCYP3A4CYP1A2
SCHEMBL1121987 0.76 HTR2A (0.58) HSD11B1CYP2C19CYP3A4CYP1A2HTR2A
SCHEMBL18423004 0.76 MAPT (0.56) CYP2C19MAPTCYP3A4L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
WO-2005047247-A1 NOVEL1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A MMP2 2721/4885MMP9 4206/4885MMP14 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.